Type 1 Interferonopathies
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
ImmuneSensor TherapeuticsIMSB301
Boehringer IngelheimBI 3000202_low dose
Clinical Trials (2)
Total enrollment: 22 patients across 2 trials
Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies
Start: Jan 2026Est. completion: Jul 20266 patients
Phase 1Recruiting
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
Start: Jul 2025Est. completion: Dec 202616 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 22 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.